Nextleaf Reports Third Quarter FY25 Results Including Fourth Consecutive Profitable Quarter

Nextleaf Solutions Ltd. (CSE: OILS,OTC:OILFF) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor, is pleased to announce its financial results for the third quarter of fiscal year 2025, ended June 30, 2025. The Company reported gross revenue of $3,769,797, net revenue of $2,912,572 and gross profit of $1,107,593. This marks the Company's fourth consecutive profitable quarter without normalization.

Q3 FY2025 Highlights

Positive Momentum on Revenue and Profitability:

Gross revenue $3,769,797 million. Net Revenue $2,912,572
Gross profit $1,107,593 million, up 25% from $884,344 in the same period last year, with a steady gross margin of 29%
Net income $867,352 YTD, up 172% from a ($1,196,316) loss for the same period in FY24
Positive EBITDA¹ at $1,112,285 YTD, highlighting the Company's operational efficiency and disciplined cost management

The Company has streamlined its product portfolio and enhanced competitiveness through targeted SKU rationalization, strategic pricing, and brand innovation to address a softer Q3.

Competitive pressure in saturated categories like high-THC vapes and infused prerolls impacted the quarter's results. Despite this, the Company has delivered profitability (without normalization) through four consecutive quarters and remains on track to exceed FY24 revenue, net income, and adjusted EBITDA targets, driven by national leadership in wellness-forward formats including softgels and oils.

Strong Balance Sheet:

The Company maintained $9.0 million in assets, and improved working capital closing the quarter with $5,601,524. An increase of 24% compared to year-end Sept 30, 2024.
The Company's debt-to-equity (D/E) ratio was reduced to 0.61 and shareholder's equity held strong at $5.6 million.

The Company ended the quarter with no secured debt, underscoring continued profitability, disciplined financial management, and a strong, undiluted equity position. This provides a solid foundation for growth without over-leveraging assets.

Commercial Expansion:

11 new product launches under flagship brand Glacial Gold across 3 categories including: 3 softgels, 5 vapes, and 3 bottled oils with national distribution.

The Company continues to focus on delivering standardized, consistent, dose-controlled extracts with high potency and purity. National product listings have driven recent success in growing categories, including full-spectrum extracts (e.g., RSO softgels), ratio-based formulations (e.g., 1:1 vapes), and minor cannabinoids (e.g., CBG and CBN oils, softgels, and vapes), reinforcing the brand's appeal to wellness-focused adult-use consumers.

"In Q3, we rapidly refined our CPG strategy-balancing both offense and defense-to protect and grow revenue from our branded portfolio, accelerate momentum in the categories we lead, and build a foothold where we've underperformed or are just entering," said Emma Andrews, CEO of Nextleaf Solutions. "We've stayed humble, agile, and innovative under pressure, and I look forward to sharing the results of these efforts in the quarters ahead-the numbers will speak for themselves."

Further performance analysis for Nextleaf's flagship brand Glacial Gold within the Canadian recreational retail market can be found at: https://www.headset.io/brands/glacial-gold

Q4 FY2025 Outlook

The Company will prioritize and allocate working capital to the following strategic initiatives throughout the fourth quarter of FY2025:

Scaling softgel innovation: Launching Canada's first 200-count softgel format with two SKUs available nationally.
Advancing consumer value in vapes through new hardware technology: Investing in next generation "post-less" vape hardware to support a new brand launch and elevate the consumer experience across existing SKUs.
Increasing operational capability: Beginning soft-opening activities (non-cannabis related) at the Company's second site, Nextleaf Distribution.
Driving retail engagement: Distributing more than 20,000 softgels to budtenders, buyers, and key retail decision-makers through a national sampling program.
Enhancing market visibility: Hosting brand activations and experiential events to strengthen relationships with buyers and national chains, with a focus on core regions.

About Nextleaf Solutions Ltd.

Nextleaf® is an innovation-driven life science company, and licensed cannabis processor with a portfolio of federally regulated emerging consumer brands, market validated cannabis derivative products, and high-potency bulk ingredients. Nextleaf's multi-patented, highly automated, closed loop extraction and distillation technology sets the global standard for processing cannabis at scale.

With coast-to-coast distribution, Nextleaf branded products and ingredients are sold through both medical and recreational channels. Featuring the acclaimed brand Glacial Gold, leading multiple categories nationally, including cannabis softgels, vapes, and oils.

The Company has been issued 19 U.S. patents, and 75+ patents globally, on cannabinoid processing including extraction, distillation, and acetylation.

On behalf of the Board of Directors of the Company,
Emma Andrews, CEO

Contact: investors@nextleafsolutions.com
Follow Nextleaf Solutions on LinkedIn
Learn More: www.nextleafsolutions.com

Nextleaf trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Disclaimers and Disclosure Statements:

Certain statements contained in this press release constitute "forward-looking statements" within the meaning of applicable securities laws. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the Company's anticipated delivery of its products to provincial markets across Canada and those regarding the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The Canadian Securities Exchange has not reviewed or approved the contents of this press release.

Non-IFRS Financial Measures

This press release includes references to "EBITDA", which are not defined under International Financial Reporting Standards (IFRS). The intent of these non-IFRS measures is to provide additional useful information to investors and analysts. These non-IFRS measures do not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other entities. As such, these non-IFRS measures should not be considered in isolation or used as a substitute for measures of performance prepared in accordance with IFRS. EBITDA is considered as a useful measure by management to understand the profitability of Nextleaf Solutions excluding the effects of certain non-operating items.

¹ Non-IFRS or supplementary financial measure. See discussion in the Non-IFRS Financial Measures advisories section of this press release below and Management Discussion & Analysis.

Corporate Logo

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264268

News Provided by Newsfile via QuoteMedia

Nextleaf Solutions CSE:OILS Tech Investing

OILS:CC

Nextleaf Solutions

Overview

Nextleaf Solutions Ltd. (CSE:OILS,OTCQB:OILFF,FWB:L0MA) is Canada’s most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. Nextleaf’s industrial-scale extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils. The company owns a portfolio of over 50 issued patents and over 55 pending patents for the extraction and distillation of cannabinoids. Nextleaf Solutions commercializes its patent portfolio through IP licensing and the wholesale of THC and CBD oils through Nextleaf Labs, a Health Canada licensed standard processor.

Nextleaf Solutions’ Company Highlights:

First public company granted a patent for the industrial-scale extraction, refinement and purification of cannabinoids.
Health Canada Standard Processing Licence and Research Licence.
Two extraction agreements signed in April 2020 to process 25 metric tons of cannabis biomass, equaling less than 15 percent of capacity.
Commenced revenue in December 2019 through a patent licensing agreement.
Closed oversubscribed $3 Million Non-Brokered Financing in May 2020.
Has over 50 issued patents and over 55 pending patents for extracting, purifying and delivering cannabinoids.
Intellectual property encompasses the end-to-end process, as well as proprietary pieces of equipment used for the refinement of crude extract and the formulation of purified THC and CBD distillate.
Nextleaf has an exclusive technology licensing agreement with BevCanna Enterprises (CSE:BEV), who utilizes the technology to manufacture a range of cannabinoid-infused beverages in their BC bottling facility with an annual capacity of over 30 million bottled beverages. Nextleaf is expected to supply cannabinoids to BevCanna under the agreement.
Fully licensed, centralized extraction processing facility, located in Greater Vancouver. 6,540 square foot facility with Phase 1 capacity to process up to 600 kilograms per day of cannabis biomass to high purity distillate.
National Research Council Grant through the Industrial Research Assistance Program (IRAP) for the development of unique processing techniques for removing chlorophyll and other impurities from crude oil extracts.
Sustainable Development Technology Canada (SDTC) $2.5 million consortium with Terramera for replacing toxic chemical pesticides with pesticides derived from natural products.
Natural Science & Engineering Research Council (NSERC) partnership with the University of British Columbia (UBC) and British Columbia Institute of Technology (BCIT), for the development of methods pertaining to repurposing incinerated cannabis waste biomass for industrial construction.
Completed bulk sale of premium THC distillate to a BC-based licensed cannabis processor.
Signed a cannabis extraction agreement with Eve & Co. (TSXV:EVE, OTCQB:EEVVFF) in November 2020.

Get access to more exclusive Cannabis Stock profiles here.

Providing Patented Cannabis Extraction Processing Services

Nextleaf Provides Update on Status of Health Canada Application for Psychedelics Dealer's Licence

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to advise that its wholly-owned subsidiary Nextleaf Labs Ltd. ("Nextleaf Labs") has received acceptance of its application for a Controlled Substances Dealer's Licence (a "Dealer's Licence"), now formally under review by Health Canada.

A Dealer's Licence will allow Nextleaf Labs to conduct a variety of activities relating to psilocybin and psilocin including research and development ("R&D"), intellectual property ("IP") development, production of base substance materials, laboratory analysis, as well as the sale and distribution of the psychedelic compounds to authorized individuals (or their compounding pharmacies), researchers and companies undertaking clinical trials, each retaining appropriate approvals for such possession and use. Health Canada targets a processing service standard of 270 calendar days from the date of receipt of an application for a Dealer's Licence.

With a full laboratory already operating under its existing Health Canada cannabis licences, Nextleaf's current site will expand its capabilities in extraction and IP development for psilocybin and other psychedelic materials upon the issuance of a Dealer's Licence from Health Canada.

Nextleaf's existing IP stack, the development of its Specialty Molecules Division, and receipt of a Dealer's Licence will allow the Company to develop a suite of standardized naturally-derived prodrugs ranging from acetylated cannabinoids to psilocybin. This may present new revenue drivers through opportunities for short-term and long-term partnerships with other industry stakeholders.

Nextleaf owns 17 U.S. patents and has been issued 95 patents globally. The Company continues to strengthen its robust IP portfolio, pursuing federally regulated production of novel psychoactive products, as large multinational pharmaceutical companies enter the space.

"With our Company's unprecedented track record securing issued U.S. patents for the extraction of cannabinoids, Nextleaf is well positioned to mirror that success with psilocybin extraction," said Paul Pedersen, co-founder and CEO of Nextleaf. "We anticipate that a Dealer's Licence will be a major catalyst with respect to Nextleaf's Specialty Molecules Division, which is focused on the development and commercialization of novel psychoactive compounds for their potential therapeutic benefits."

CannDelta Co-founder and CEO Dr. Sherry Boodram

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5347/103954_0857d55c846d6beb_001full.jpg

Nextleaf engaged CannDelta Inc. ("CannDelta") with respect to its application for a Dealer's Licence. Dr. Sherry Boodram is the co-founder & CEO of CannDelta, which includes PsyDelta, a dedicated psychedelics service. Prior to founding CannDelta, Dr. Boodram spent several years in the Canadian federal government, most notably with Health Canada's Medical Cannabis Program and Controlled Substances Program as a Senior Regulatory Compliance and Enforcement Officer. She was responsible for licensing application reviews and on-site facility inspections under the legislative regimes of the Marihuana for Medical Purposes Regulations (MMPR), Access to Cannabis for Medical Purposes Regulations (ACMPR), and the Controlled Drugs and Substances Act. Dr. Boodram holds a Ph.D. in Chemistry from York University, a B.Sc. (Hon) from the University of Toronto, a Certificate in Cannabis Law and Regulation from Osgoode Hall Law School of York University, and a Graduate Certificate with Honours in Pharmaceutical Regulatory Affairs and Quality Operations from Seneca College. Dr. Boodram is also an elected board member of the Canadian Association of Professionals in Regulatory Affairs (CAPRA).

As a leading expert in cannabis and psychedelic science and regulation, Dr. Boodram, hosted a distinguished panel discussion with other experts, titled "Developing Psychedelic Medicine Beyond What We Already Know" at the world's largest psychedelic business conference, Wonderland Miami Conference, on November 8-9, 2021.

Dr. Sherry Boodram has served as an independent board member of Nextleaf since October of 2019.

Medical Access and Therapeutic Relief for Veterans

The veteran community has made it clear that they need and deserve a reliable supply of consistent quality medical cannabis products and psychedelics for those living with PTSD, chronic pain, and other conditions that disproportionately impact veterans. According to a 2019 Veterans Health and Medical Cannabis Study^[1], 96% of veterans reported they experience a much greater quality of life because of their cannabis consumption. As part of the Company's commitment to improving access to medical cannabis and psychoactive compounds for therapeutic benefit, Nextleaf has launched an assortment of accessibly priced medical cannabis products well suited to the veteran community's needs. This includes large format distilled oils with the best dollar value per milligram for CBD in Canada, the highest potency CBD oil legally available in Canada, as well as CBD and THC vapes under the Glacial Gold™ brand. These products will soon be distributed nationally through www.mendocannabis.ca.

Nextleaf CEO to Present at 2021 Lift&Co. Cannabis Business Conference

Nextleaf will participate in the 2021 Lift&Co. Expo at Toronto's Metro Toronto Convention on Nov 18-21. The event will consist of over 200 exhibitors including publicly-traded cannabis and psychedelic companies, and feature relevant panels and keynote speakers in both the cannabis and psychedelic space.

Nextleaf's CEO Paul Pedersen will be speaking on a panel discussion that includes Weedmaps (NASDAQ: MAPS) CEO Chris Beals, titled "Ancillary Industries: Bottom-Line Wisdom and Warnings from Ancillary Industry Leaders" at 4:15pm ET on November 18. For more information about the event, visit https://liftexpo.ca/.

About Nextleaf®

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids. Nextleaf distributes cannabis vapes and distilled oils under its award-winning prohibition-era brand, Glacial Gold™, and supplies cannabis distillate to its wholesale customers. Nextleaf's patented closed-loop automated extraction plant in Metro Vancouver efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale. Nextleaf is developing proprietary delivery technology and formulations through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company owns 17 U.S. patents and has been issued 95 patents globally.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, and Instagram.

www.nextleafsolutions.com

Follow Glacial Gold™ across social platforms: Instagram, Twitter, and Facebook. www.Glacial.Gold

For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
jason@nextleafsolutions.com

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio, receipt of the Dealer's Licence within the anticipated timeframe or at all, the activities the Company expects to conduct if the Dealer's Licence, the ability of the Company to develop and protect intellectual property relating to psychedelics, the expected benefits to the Company if the Dealer's Licence is received, the Dealer's License assisting the company in obtaining a unique position for the Company to develop a suite of standardized plant-derived drugs, the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nextleaf Launches Highest Potency CBD Oil in Canada

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, announced today the launch of Distilled CBD 100 Oil & Distilled CBD 200 Oil under the Company's prohibition-era brand Glacial Gold™.

Glacial Gold™ Distilled CBD 200 Oil is a first in Canada's adult-use and medical markets, with the highest amount of CBD in a single unit (5700 mg), highest potency of CBD available in an ingestible oil format (200 mg/g = 20 %), and best dollar value per milligram for CBD in both the legal and illicit markets in Canada.

Glacial Gold Distilled CBD 100 Oil & Distilled CBD 200 Oil

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/5347/101830_7c37128fd436f93a_001full.jpg

The Company's multi-patented winterization and filtration technology is the secret behind producing high-purity CBD distillate free of waxes, sugars, and other undesirable compounds.

A recent CBC Marketplace investigation report showed that the unregulated market for CBD is rife with misleading claims and contaminants that are harmful for consumers and would not meet standards within the regulated market^[1].

"We are proud to be the first Company to launch a high-potency CBD product in Canada. By leveraging Nextleaf's competitive advantage producing high-purity distillate at scale, we are able to offer the lineup of Glacial Gold CBD products at disruptive price points," said Nextleaf CEO and co-founder Paul Pedersen. "When consumers purchase Glacial Gold products, they have a confidence that every millilitre is standardized for a predictable, safe, and repeatable outcome that simply cannot be guaranteed in products available from illicit sources, including unregulated CBD products produced in the United States".

Based on the early success of Glacial Gold™ Distilled CBD 50 Oil through retailers in British Columbia, Nextleaf is launching its new Glacial Gold™ Distilled CBD 100 & Distilled CBD 200 Oils. This expands the Glacial Gold lineup of Distilled CBD Oil offerings into a range of potencies for low, medium, and high dose CBD consumers. All Glacial Gold CBD Oil products are produced by Nextleaf using sun-grown hemp.

Glacial Gold™ CBD and THC products are currently sold across British Columbia, with plans to expand nationally next year.

Glacial Gold™ products are being made available to medical cannabis patients across Canada through mendocannabis.ca.

Glacial Gold™ 60 Day Review

Nextleaf launched its prohibition-era brand Glacial Gold™ in British Columbia, the Company's home province, in early September. After two months of sales, the brand continues to garner national attention for its quality distillate and accessible pricing from consumers, patients, and retailers, alike. Nextleaf continues to see increased demand within the province of British Columbia including higher volume purchase orders. A few key milestones and metrics over the September and October months:

Launched 7 SKUs of Glacial Gold™ THC and CBD products in B.C., consisting of four 1-gram vape SKUs and three distilled oil SKUs
The addition of Distilled CBD 100 & CBD 200 Oils amounts to 9 Glacial Gold™ SKUs listed in B.C. within the first 60 days of initial launch
60%+ retail penetration rate with Glacial Gold™ in B.C.
Top value 1g vape cart in Canada (Anytime 1:1 Vape)
Top value CBD oil in Canada (Distilled CBD 50 Oil)
Signed an agreement with Quebec-based medical cannabis platform Mendocannabis.ca for distribution of Glacial Gold™ to medical cannabis patients across Canada
Signed agreement with National Cannabis Distribution Inc., a wholly-owned subsidiary of Kiaro Holdings Corp., for distribution of Glacial Gold™ in Saskatchewan

About Nextleaf®

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids. Nextleaf distributes cannabis vapes and distilled oils under its award-winning prohibition-era brand, Glacial Gold™, and supplies cannabis distillate to its wholesale customers. Nextleaf's proprietary closed-loop automated extraction plant in Metro Vancouver efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale. Nextleaf is developing delivery technology and differentiated cannabinoid-based formulations through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company owns 17 U.S. patents and has been issued 90 patents globally.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, and Instagram.
www.nextleafsolutions.com

Follow Glacial Gold™ across social platforms: Instagram, Twitter, and Facebook. www.Glacial.Gold

For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
jason@nextleafsolutions.com

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio, the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nextleaf Launches Glacial Gold Vapes and Distilled Oils Through Quebec-based Medical Cannabis Platform

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce the Company has entered into a supply agreement with Quebec-based licensed producer Medicibis ("Mendo") to supply its medical platform www.Mendocannabis.ca with Glacial Gold™ branded products.

Mendo operates an online portal for medical patients that ships nationwide through www.Mendocannabis.ca. Glacial Gold™ CBD and THC vapes and distilled oils will be distributed by Mendo to their medical cannabis clients in Quebec and across Canada.

Quebec is the third-largest cannabis market in Canada, representing approximately 15%^[1] of Canadian cannabis retail sales in the country, and approximately 22% of the Canadian population^[2].

Figure 1: Glacial Gold CBD and THC Vapes and Distilled Oils

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/5347/100149_54a84d0cc4d15940_001full.jpg

Canadian spending on medical cannabis totaled $587 million in 2020^[3]. Medical cannabis has become an important component of Canadian healthcare, with $119 million of medical cannabis purchases reimbursed by the Federal Government through Veterans Affairs Canada in 2020^[4]. Despite Canada's progressive cannabis regulation, price is still a major barrier for many medical patients.

Nextleaf leverages its patented high-efficiency ingredient processing technology to gain a competitive advantage and improve cannabis oil economics through the low-cost production of cannabis distillate standardized for potency and purity.

"Launching accessibly priced Glacial Gold™ vapes and distilled oils in Canada's medical market and in Quebec have been important milestones for Nextleaf. We believe Mendo and their Quebec-based medical platform is positioned to become one of the leading suppliers of medical cannabis to patients and veterans in this country," said Paul Pedersen, co-founder and CEO of Nextleaf Solutions. "Our innovative technology enables us to produce high purity ingredients at a low cost per molecule to offer patients quality CBD and THC products."

"We are delighted to work with Nextleaf to offer Glacial Gold™ products through our recently expanded national portal, accessible by medical patients Canada-wide," said Jay Schwartz, Director of Mendo Medical. "We are excited to feature the seven Glacial Gold™ SKUs that launched last month in British Columbia and to help them launch two new CBD SKUs that we think patients will be eager to experience."

Nextleaf launched its award-winning, prohibition-era brand Glacial Gold™ in British Columbia last month, receiving national attention for quality products at disruptive price points. Included in the initial launch of Glacial Gold™ were seven total SKUs, consisting of four 1-gram vape SKUs and three distilled oil SKUs.

Glacial Gold^™Distilled CBD 50 Oil, Distilled THC 30 Oil, and Distilled 30:30 Blend feature high-purity distillate in a base of organic coconut MCT oil for a premium consumption experience, without premium pricing. A clean tasting and neutral oil allows for the greatest flexibility in use and consumption occasions.

The initial vape lineup from Glacial Gold^™ is offered in two potency levels to match the consumer's tolerance level or consumption occasion. The Session THC Vape features a full potency THC profile for cannabis enthusiasts who seek a more elevated experience and connection. The Anytime 1:1 Vape is formulated with a balanced THC and CBD profile for consumers looking for a more moderate, go-to vape.

About Medicibis

Medicibis is a federally licensed producer of dried cannabis and distributes its products under the brand name ENDO. Medicibis operates out of its 20,000 sq.ft. facility located 15 minutes from downtown Montreal in St Jean Sur Richelieu. Medicibis operates an online portal for medical patients that ships nationwide through their website mendocannabis.ca. Mendo's menu has been carefully curated to offer a variety of products from licensed producers from all over Canada. Mendo is positioned to become one of the leading suppliers of medical cannabis to patients and veterans in the country.

About Nextleaf®

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids. Nextleaf distributes cannabis vapes and distilled oils under its award-winning prohibition-era brand, Glacial Gold™, and supplies cannabis distillate to its wholesale customers. Nextleaf's proprietary closed-loop automated extraction plant in Metro Vancouver efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale. Nextleaf is developing delivery technology and differentiated cannabinoid-based formulations through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company owns 17 U.S. patents and has been issued 95 patents globally.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, and Instagram.
www.nextleafsolutions.com

Follow Glacial Gold™ across social platforms: Instagram, Twitter, and Facebook. www.Glacial.Gold

For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
jason@nextleafsolutions.com

On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio, the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Nextleaf Releases Key Metrics from Inaugural Month of Sales of Glacial Gold Vapes and Distilled Oils

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids, is pleased to announce key metrics from the launch of Glacial Gold™ in British Columbia. Included in the inaugural month of sales of Glacial Gold™ were seven total Stock Keeping Units ("SKUs"), consisting of four 1-gram vape SKUs and three distilled oil SKUs.

First order shipped to the BCLDB on September 3, 2021
Over 20,000+units of Glacial Gold™ vape cartridges and distilled oils were shipped to the British Columbia Liquor Distribution Branch over the first four weeks
Retail value of all units shipped during first month of sales was over $750,000
50%+ retail penetration rate with Glacial Gold™ products already sold in more than half of British Columbia's 370+ government and private retail locations^[1]
Top value THC vape cart in B.C. (Session Vape 1g)
Top value 1:1 vape cart in B.C. (Anytime 1:1 Vape 1g)
Top value CBD oil in B.C. (Distilled CBD 50 Oil 30ml)
Top value 1:1 oil in B.C. (Distilled 30:30 Oil 30ml)

The initial vape lineup from Glacial Gold^™ is offered in two potency levels to match a consumers tolerance level or consumption occasion. The Session THC Vape features a full potency THC profile for cannabis enthusiasts who seek a more elevated experience and connection. The Anytime 1:1 Vape is formulated with a balanced THC and CBD profile for consumers looking for a more moderate, go-to vape. Flavours include Glacial Fresh Mint with refreshing alpine aromas found in the B.C. backcountry, and Berry Lemonade, reminiscent of fresh-picked berries from the Okanagan.

Glacial Gold^™Distilled CBD 50 Oil, Distilled THC 30 Oil, and Distilled 30/30 Blend feature high-purity distillate in a base of organic MCT (medium chain triglycerides) oil for a premium consumption experience, without premium pricing. A clean tasting, and neutral oil allowing for the greatest flexibility in use and consumption occasions.

Figure 1: Distilled CBD 50 Oil 30ml

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/5347/98610_dadb47bc04883af3_001full.jpg

"We're excited how the Glacial Gold^™ brand of Session and Anytime vapes and Distilled Oils has resonated amongst private retailers and consumers across British Columbia," said Nextleaf co-founder and CEO Paul Pedersen. "We've launched Glacial Gold^™ with the goal of holding a top five category position with our vapes and oils by delivering on the brand promise of unparalleled value through high-quality products at accessible price points."

Nextleaf Delivers Vape Cartridges to Atlantic Canadian Partner

Nextleaf, through its wholly-owned subsidiary Nextleaf Labs Ltd. ("Nextleaf Labs"), has shipped its second delivery of vape cartridges to an Atlantic Canada partner (the "Partner"). In total Nextleaf Labs has delivered over 20,000 units of 1-gram THC vape cartridges to the Partner.

About Nextleaf®

Nextleaf is a federally regulated producer of cannabis oil that owns one of the largest portfolios of U.S. patents for the extraction and distillation of cannabinoids. Nextleaf distributes cannabis vapes and distilled oils under its award-winning prohibition-era brand, Glacial Gold™, and supplies cannabis distillate to its wholesale customers. Nextleaf's proprietary closed-loop automated extraction plant in Metro Vancouver efficiently transforms cannabis and hemp grown in B.C. and throughout Canada into high-purity cannabis distillate at an industrial scale. Nextleaf is developing delivery technology and differentiated cannabinoid-based formulations through its Health Canada Research Licence with sensory evaluation of cannabis via human testing. The Company owns 17 U.S. patents and has been issued 90 patents globally.

Nextleaf Solutions trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.

Follow the Company across social platforms: Twitter, LinkedIn, Facebook, and Instagram.
www.nextleafsolutions.com

Follow Glacial Gold™ across social platforms: Instagram, Twitter, and Facebook. www.Glacial.Gold

For more information please contact:
Jason McBride, Corporate Development
604-283-2301 (ext. 219)
jason@nextleafsolutions.com

On behalf of the Board of Directors of the Company,

Paul Pedersen, CEO

Certain statements contained in this press release constitute "forward-looking statements". All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company's ability to capitalize on its IP portfolio, the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The CSE has not reviewed or approved the contents of this press release.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Homerun Resources Inc. Signs Binding LOI for the Acquisition of Additional Mineral Rights in the Santa Maria Eterna Silica Sand District

News Release Highlights:

Homerun has now secured ownership and supply agreements covering the entire Santa Maria Eterna Silica Sand District.
The new Pedreiras concession is fully permitted with a low royalty rate of R$ 30.17 per extracted tonne.
The Pedreiras concessions have been drilled to a depth of 8 metres with a 32 million tonne resource filed at the Agência Nacional de Mineração (ANM).
The Company's target resource under the three CBPM Lease acquisitions now exceeds 200 million tonnes.

Homerun Resources Inc. (TSXV: HMR,OTC:HMRFF) (OTCQB: HMRFF) ("Homerun" or the "Company") is pleased to announce it has signed a binding Letter of Intent (LOI) with Pedreiras do Brasil S.A. ("Pedreiras") a company controlled by Vitoria Stone, dated September 10, 2025, securing the rights to exploit the Pedreiras mining tenement (871.7212021, 246.36 hectares) at the Santa Maria Eterna Silica Sand District in the municipality of Belmonte, Bahia, Brazil, granted under a lease agreement with Companhia Bahiana de Pesquisa Mineral (CBPM).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

Gold Investing

Nextleaf Reports Third Quarter FY25 Results Including Fourth Consecutive Profitable Quarter

Nextleaf Solutions

Overview

Nextleaf Solutions’ Company Highlights:

Nextleaf Provides Update on Status of Health Canada Application for Psychedelics Dealer's Licence

Nextleaf Launches Highest Potency CBD Oil in Canada

Nextleaf Launches Glacial Gold Vapes and Distilled Oils in Saskatchewan

Nextleaf Launches Glacial Gold Vapes and Distilled Oils Through Quebec-based Medical Cannabis Platform

Nextleaf Releases Key Metrics from Inaugural Month of Sales of Glacial Gold Vapes and Distilled Oils

Completion of Non-Renounceable Pro-Rata Entitlement Offer

Homerun Resources Inc. Signs Binding LOI for the Acquisition of Additional Mineral Rights in the Santa Maria Eterna Silica Sand District

UK Revenue Update

CG1O: Security Class Suspension from Quotation

FY25 Results Presentation

Appendix 4E Annual Report FY25

Latest News

Apple debuts iPhone 17

Introducing iPhone Air, a powerful new iPhone with a breakthrough design

Apple unveils iPhone 17 Pro and iPhone 17 Pro Max, the most powerful and advanced Pro models ever

Latest Press Releases

High-Grade Copper-Gold Extensions at Nugent

Over 50% Q-o-Q Production Growth Targeted

Analyst Report: Locksley’s US Strategy Strengthens Critical Minerals Position

Altech Batteries Ltd Annual Report to Shareholders

Related News

High-Grade Copper-Gold Extensions at Nugent

Over 50% Q-o-Q Production Growth Targeted

Analyst Report: Locksley’s US Strategy Strengthens Critical Minerals Position

John Feneck: Next Gold, Silver Price Targets, 11 Stocks I'm Bullish on Now

Sun Summit Minerals Eyes "Multimillion-Ounce" Gold Deposit at JD Project

Altech Batteries Ltd Annual Report to Shareholders

Gold Sector Consolidation Ramps Up with Newmont, Alamos and First Nordic Deals

TOP STOCKS